Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Johanna Gellert"'
Autor:
Patrik Kehler, Timo Lischke, Antje Danielczyk, Johanna Gellert, Theresa Neumann, Evelyn Hartung, Stephanie Gurka, Naomi Kast, Lisa Weiß, Luisa Willmann, Sophie Marinoff, Sven Barke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/f0248c5c8a474100a458920fd4f8c689
Autor:
Theresa Neumann, Evelyn Hartung, Johanna Gellert, Lisa Weiß, Manon Weiske, Naomi Kast, Stephanie Gurka, Sophie Marinoff, Anika Jäkel, Antje Danielczyk, Patrik Kehler
Publikováno v:
Frontiers in Drug Discovery, Vol 3 (2023)
Introduction: One of the most drastic changes in cancer is the altered glycosylation of proteins and lipids, giving rise to truncated O-glycans like the Thomsen Friedenreich (TF) or Thomsen nouvelle (Tn) antigen, which are almost absent on normal cel
Externí odkaz:
https://doaj.org/article/1642fa48651b41748ba0b68dfa45fd4f
Autor:
Anna Christina Dragon, Luca Marie Beermann, Melina Umland, Agnes Bonifacius, Chiara Malinconico, Louisa Ruhl, Patrik Kehler, Johanna Gellert, Lisa Weiß, Sarah Mayer-Hain, Katharina Zimmermann, Sebastian Riese, Felicitas Thol, Gernot Beutel, Britta Maecker-Kolhoff, Fumiichiro Yamamoto, Rainer Blasczyk, Axel Schambach, Michael Hust, Michael Hudecek, Britta Eiz-Vesper
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionChimeric antigen receptor-engineered T cells (CAR-Ts) are investigated in various clinical trials for the treatment of cancer entities beyond hematologic malignancies. A major hurdle is the identification of a target antigen with high exp
Externí odkaz:
https://doaj.org/article/46ba9e9337d34affb73dc677378f3afa
Autor:
Anika Jaekel, Patrik Kehler, Timo Lischke, Christoph Goletz, Anke Flechner, Antje Danielczyk, Johanna Gellert
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/6dfe5e8da513473db627f741b64f95a0
Autor:
Patrik Kehler, Theresa Neumann, Anika Jaekel, Johanna Gellert, Antje Danielczyk, Lisa Weiß, Luisa Willmann, Stephanie Gurka, Naomi Kast, Manon Weiske
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0feef532eb2b18842364c904cfe099d0
https://doi.org/10.1136/jitc-2022-sitc2022.1347
https://doi.org/10.1136/jitc-2022-sitc2022.1347
Autor:
Patrik Kehler, Theresa Neumann, Anika Jaekel, Manon Weis, Johanna Gellert, Antje Danielczyk, Evelyn Hartung, Timo Lischke, Stephanie Gurka, Naomi Kast, Manon Weiske
Publikováno v:
Regular and Young Investigator Award Abstracts.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::00fc472e81e39f9c863f2968284069b1
https://doi.org/10.1136/jitc-2022-sitc2022.1346
https://doi.org/10.1136/jitc-2022-sitc2022.1346
Autor:
Patrik Kehler, Anika Jaekel, Antje Danielczyk, Christoph Goletz, Timo Lischke, Evelyn Hartung, Lisa Weiß, Manon Weis, Stephanie Gurka, Sophie Marinoff, Naomi Kast, Manon Weiske, Marianne Morche, Johanna Gellert, Theresa Neumann
Publikováno v:
Cancer Research. 82:316-316
Background: Highly potent therapeutic approaches require very clean targets. However, the majority of antibodies in clinical development or approved for cancer therapy address protein targets that are only overexpressed on cancer cells and yet often
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::153c4b21ea1f186d7b72b8327ed12c6d
https://doi.org/10.1158/1538-7445.am2022-316
https://doi.org/10.1158/1538-7445.am2022-316
Autor:
Patrik Kehler, Anika Jaekel, Johanna Gellert, Christoph Goletz, Timo Lischke, Anke Flechner, Antje Danielczyk, Theresa Neumann
Publikováno v:
Cancer Research. 82:2879-2879
Introduction: IL-15 is a potent pro-inflammatory cytokine that enhances the differentiation, proliferation and cytolytic activity of NK cells and T cells. Due to the huge potential of IL-15 to activate both innate and adaptive anti-tumor immunity, se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::095d80b298106546d08186f523a4027c
https://doi.org/10.1158/1538-7445.am2022-2879
https://doi.org/10.1158/1538-7445.am2022-2879
Autor:
Patrik Kehler, Johanna Gellert, Sven Bahrke, Christoph Goletz, Lisa Weiß, Anika Jaekel, Flechner Anke, Timo Lischke, Antje Danielczyk, Evelyn Hartung
Publikováno v:
Journal for ImmunoTherapy of Cancer. 9:A816-A816
BackgroundThe Lewis Y (CD174) carbohydrate antigen is widely expressed in primary and metastatic epithelial tumors like colon, lung, ovarian, and breast. Targeting Lewis Y for cancer therapy was pursued before, however, other anti-Lewis Y antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f1f3bd93c06f8eb92339049341a1dd23
https://doi.org/10.1136/jitc-2021-sitc2021.781
https://doi.org/10.1136/jitc-2021-sitc2021.781
Autor:
Patrik Kehler, Christoph Goletz, Johanna Gellert, Antje Danielczyk, Flechner Anke, Anika Jaekel, Timo Lischke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundIL-15 is a potent pro-inflammatory cytokine that enhances the differentiation, proliferation and cytolytic activity of NK cells and T cells. Due to the huge potential of IL-15 to activate both innate and adaptive anti-tumor immunity, severa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::508b5fe75ecab7283f5e083a883aac3d
https://doi.org/10.1136/jitc-2021-sitc2021.712
https://doi.org/10.1136/jitc-2021-sitc2021.712